Stock Events

Stock Events

Immunovant 

$29.17
59
-$0.47-1.59%Friday 19:59
+$0.40+1.37%Friday 23:39After hours

Statistics

Day High
29.19
Day Low
29.11
52W High
45.42
52W Low
21.43
Volume
54,860
Avg. Volume
-
Mkt Cap
6.03B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 9Expected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-0.75
-0.7
-0.64
-0.59
Expected EPS
-0.737014
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-505.61MNet Income

Analyst Ratings

$47.67Average Price Target
The highest estimate is ⁦62.00⁩.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
83%
Hold
17%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMVT. It's not an investment recommendation.
Apple
11
AAPL
Amazon
11
AMZN
NVIDIA
11
NVDA
Microsoft
10
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Argen X
ARGX
Mkt Cap57.51B
argenx competes directly with Immunovant in developing treatments for autoimmune diseases, specifically targeting the FcRn pathway similar to Immunovant's approach.
United Community Banks
UCB
Mkt Cap4.11B
UCB is involved in creating therapies for autoimmune and inflammatory diseases, competing in the same therapeutic areas as Immunovant.
Abbvie
ABBV
Mkt Cap464.43B
AbbVie has a broad portfolio in immunology, including treatments for autoimmune diseases, making it a competitor in the same market as Immunovant.
AMGEN
AMGN
Mkt Cap217.9B
Amgen's focus on novel therapeutics in inflammation and immunology positions it as a competitor to Immunovant in the autoimmune disease space.
GSK
GSK
Mkt Cap94.23B
GlaxoSmithKline has a diverse immunology pipeline that includes treatments for autoimmune diseases, competing with Immunovant's therapeutic focus.
Regeneron Pharmaceuticals
REGN
Mkt Cap75.69B
Regeneron Pharmaceuticals, known for its innovative therapies in immunology, competes with Immunovant in developing treatments for autoimmune diseases.
Novartis
NVS
Mkt Cap268B
Novartis has a strong presence in the immunology and dermatology space, making it a competitor to Immunovant in developing autoimmune disease treatments.
Bristol-Myers Squibb
BMY
Mkt Cap124.91B
Bristol Myers Squibb's extensive research in immune system modulation and autoimmune diseases places it as a competitor to Immunovant.

About

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
Show More
CEO
Eric Venker
Employees
315
Country
United States
ISIN
US45258J1025

Listings

XNAS
US
IMVT
BOATS
BOATS
IMVT.BOATS

0 Comments

Share your thoughts

FAQs

What is Immunovant stock price today?▼
The current price of IMVT is $29.17 USD — it has decreased by -1.59% in the past 24 hours. Watch Immunovant stock price performance more closely on the chart.
What is Immunovant stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Immunovant stocks are traded under the ticker IMVT.
Is Immunovant stock price growing?▼
IMVT stock has risen by +3.55% compared to the previous week, the month change is a -13.24% fall, over the last year Immunovant has showed a +18.19% increase.
What is Immunovant market cap?▼
Today Immunovant has the market capitalization of 6.03B
When is the next Immunovant earnings date?▼
Immunovant is going to release the next earnings report on November 9, 2026.
What were Immunovant earnings last quarter?▼
IMVT earnings for the last quarter are -0.75 USD per share, whereas the estimation was -0.63 USD resulting in a -19.26% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Immunovant revenue for the last year?▼
Immunovant revenue for the last year amounts to 0 USD.
What is Immunovant net income for the last year?▼
IMVT net income for the last year is -505.61M USD.
How many employees does Immunovant have?▼
As of November 2, 2026, the company has 315 employees.
In which sector is Immunovant located?▼
Immunovant operates in the Health & Wellness sector.
When did Immunovant complete a stock split?▼
Immunovant has not had any recent stock splits.
Where is Immunovant headquartered?▼
Immunovant is headquartered in DURHAM, United States.